Human red blood cells alterations in primary aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2494-2501

  Bordin, Luciana ^a   Donà, Gabriella ^a   Sabbadin, Chiara ^a   Ragazzi, Eugenio ^a   Andrisani, Alessandra ^a   Ambrosini, Guido ^a   Brunati, Anna Maria ^a   Clari, Giulio ^a   Armanini, Decio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANRENONE; HYDROCORTISONE; IMMUNOGLOBULIN G; TYROSINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OXIDATIVE STRESS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE POOR PLASMA;

ADULT; AGED; ANION EXCHANGE PROTEIN 1, ERYTHROCYTE; DIAMIDE; ERYTHROCYTE AGGREGATION; ERYTHROCYTES; FEMALE; HUMANS; HYPERALDOSTERONISM; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84878509046     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3571     Document Type: Article

References (44)

1. Booth RE, Johnson JP, Stockand JD. Aldosterone. Adv Physiol Educ. 2002;26:8-20.
2. Robert-Nicoud M, Flahaut M, Elalouf JM, et al. Transcriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci USA. 2001;98:2712-2716. (Pubitemid 32209548)
3. Yang J, Fuller PJ. Interactions of the mineralocorticoid receptor - within and without. Mol Cell Endocrinol. 2012;350:196-205.
4. Yang J, Chang CY, Safi R, et al. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol Endocrinol. 2011;25:32-43.
5. Boldyreff B, Wehling M. Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant. 2003;18:1693-1695. (Pubitemid 37098534)
6. Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350:223-234.
7. Reil JC, Hohl M, Selejan S, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098-2108.
8. Funder JW. Medicine. The genetics of primary aldosteronism. Science. 2011;331:685-686.
9. Funder JW. Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertens Res. 2010;33:872-875.
10. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
11. Shibata S, Fujita T. Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Mol Cell Endocrinol. 2012;350:273-280.
12. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49:578-597. (Pubitemid 26051838)
13. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978;14:228-235. (Pubitemid 9014989)
14. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262. (Pubitemid 29056953)
15. Qin W, Rudolph A, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76. (Pubitemid 36859043)
16. Nakamura T, Kataoka K, Fukuda M, et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension. 2009;54:544-551.
17. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486-493.
18. Patni H, Mathew JT, Luan L, Franki N, Chander PN, Singhal PC. Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol. 2007;293:F1065-F1071. (Pubitemid 47583938)
19. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55. (Pubitemid 36849598)
20. Stadtman ER, Levine RL. Protein oxidation. Ann NY Acad Sci. 2000;899:191-208. (Pubitemid 30352787)
21. Pacifici RE, Davies KJ. Protein degradation as an index of oxidative stress. Methods Enzymol. 1990;186:485-502. (Pubitemid 20279991)
22. Bordin L, Fiore C, Zen F, Coleman MD, Ragazzi E, Clari G. Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding. Br J Pharmacol. 2010;161:1186-1199.
23. Bordin L, Ion-Popa F, Brunati AM, Clari G, Low PS. Effector-induced Syk-mediated phosphorylation in human erythrocytes. Biochim Biophys Acta. 2005;1745:20-28.
24. Bordin L, Quartesan S, Zen F, Vianello F, Clari G. Band 3 Tyr-phosphorylation in human erythrocytes from non-pregnant and pregnant women. Biochim Biophys Acta. 2006;1758:611-619.
25. Jennings ML. Kinetics and mechanism of anion transport in red blood cells. Annu Rev Physiol. 1985;47:519-533. (Pubitemid 15142395)
26. Ferru E, Giger K, Pantaleo A, et al. Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3. Blood. 2011;117:5998-6006.
27. Lutz HU, Fasler S, Stammler P, Bussolino F, Arese P. Naturally occurring anti-band 3 antibodies and complement in phagocytosis of oxidatively-stressed and in clearance of senescent red cells. Blood Cells. 1988;14:175-203.
28. Bosman GJ, Willekens FL, Werre JM. Erythrocyte aging: a more than superficial resemblance to apoptosis? Cell Physiol Biochem. 2005;16:1-8. (Pubitemid 41197082)
29. Bosman GJ, Lasonder E, Groenen-Döpp YA, Willekens FL, Werre JM, Novotný VM. Comparative proteomics of erythrocyte aging in vivo and in vitro. J Proteomics. 2010;73:396-402.
30. Bratosin D, Mazurier J, Tissier JP, et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie. 1998;80:173-195. (Pubitemid 28185056)
31. Bordin L, Zen F, Ion-Popa F, Barbetta M, Baggio B, Clari G. Band 3 Tyr-phosphorylation in normal and glucose-6-phosphate dehydrogenase-deficient human erythrocytes. Mol Membr Biol. 2005;22:411-420. (Pubitemid 41747103)
32. Bordin L, Fiore C, Donà G, et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril. 2010;94:1616-1621.
33. Donà G, Ragazzi E, Clari G, Bordin L. Hemolysis and anemia induced by dapsone hydroxylamine. In: Silverberg DS, ed. Anemia. New York: InTech; 2012;425-440.
34. Donà G, Sabbadin C, Fiore C, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703-710.
35. Fiore C, Bordin L, Pellati D, Armanini D, Clari G. Effect of glycyrrhetinic acid on membrane band 3 in human erythrocytes. Arch Biochem Biophys. 2008;479:46-51.
36. Tekkatte C, Vidyasekar P, Kapadia NK, Verma RS. Enhancement of adipogenic and osteogenic differentiation of human bone-marrow-derived mesenchymal stem cells by supplementation with umbilical cord blood serum. Cell Tissue Res. 2012;347:383-395.
37. Bledsoe RK, Madauss KP, Holt JA, et al. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem. 2005;280:31283-31293. (Pubitemid 41291866)
38. Pinder JC, Pekrun A, Maggs AM, Brain AP, Gratzer WB. Association state of human red blood cell band 3 and its interaction with ankyrin. Blood. 1995;85:2951-2961.
39. Spitz IM. Proven and potential clinical applications of mifepristone (RU486). Rev Endocr Metab Disord. 2002;3:267-275.
40. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585. (Pubitemid 18263202)
41. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994;105:R11-R17.
42. Cole TJ. Cloning of the mouse 11β-hydroxysteroid dehydrogenase type 2 gene: tissue specific expression and localization in distal convoluted tubules and collecting ducts of the kidney. Endocrinology. 1995;136:4693-4696.
43. Kay M. Immunoregulation of cellular life span. Ann NY Acad Sci. 2005;1057:85-111. (Pubitemid 43211629)
44. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.